Baby plant bionic fetal fat with obvious soothing effect and preparation method thereof
By using natural ingredients such as shea butter, cetyl alcohol, caprylic/capric triglycerides in skin care products, a plant bionic phenolic fat for babies with obvious soothing effects is prepared, and the solution is to solve the problem of natural ingredients such as shea butter, cetyl alcohol, caprylic/capric triglycerides, etc. The existing skin care products have poor effect on infant skin inflammation and eczema, achieving effective skin moisturizing and protective effects.
Patent Information
- Application Number
- CN202411094814.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-10
- Publication Date
- 2024-11-22
AI Technical Summary
Existing skin care products are not effective for infant skin inflammation and eczema, and lack specialized soothing skin care products.
Using shea butter, cetaceanol, caprylic/capric triglycerides, beeswax and other natural ingredients, such as phytosterols, to prepare plant biomimetics for infants with obvious soothing effects through specific preparation methods. Fetal fat.
Effectively isolate, soothe and anti-inflammatory, enhance skin moisturizing and protective capabilities, and significantly inhibit skin problems such as eczema in children.
Smart Images

Figure CN118986795A_ABST
Abstract
Description
Technical Field
[0001] The invention relates to the technical field of daily chemical products, and in particular to plant bionic vernix caseosa for infants with obvious soothing effect and a preparation method thereof. Background Art
[0002] Inflammation is what people usually call "inflammation". It is a defensive response of the body to stimulation, which manifests as redness, swelling, heat, pain and dysfunction.
[0003] Inflammation can be infectious inflammation caused by infection or non-infectious inflammation not caused by infection. Generally, inflammation is beneficial and is an automatic defense response of the human body, but sometimes, inflammation is also harmful, such as attack on the body's own tissues, inflammation in transparent tissues, etc. In the process of inflammation, on the one hand, the damaging factors directly or indirectly cause damage to tissues and cells, and on the other hand, through inflammatory congestion and exudation reactions, the damaging factors are diluted, killed and surrounded. At the same time, the damaged tissues are repaired and healed through the regeneration of parenchymal and interstitial cells. Therefore, it can be said that inflammation is a unified process of damage and anti-damage. Acute inflammation is characterized by redness, swelling, pain, etc. as the main symptoms, that is, inflammation mainly caused by the reaction of the vascular system. Local blood vessels dilate, blood flows slowly, and blood components such as plasma and neutrophils seep into the tissues. Inflammation is most obvious when it is inflammation on the surface of the body, and it is often manifested as redness, swelling, heat, pain and dysfunction.
[0004] Skin inflammation, blood vessels, and barriers may cause mild symptoms such as skin sensitivity and damaged skin barriers. Severe cases may lead to skin diseases of varying degrees, such as acne, rosacea, seborrheic dermatitis, hormone-dependent dermatitis, perioral dermatitis, chloasma, etc.
[0005] Clinically, the treatment for skin problems such as infant eczema is still mainly based on medicines, and there is a lack of specialized auxiliary skin care products.
[0006] Therefore, how to provide a baby skin care product with obvious soothing effect is a technical problem that urgently needs to be solved in this field. Summary of the invention
[0007] The invention provides a plant bionic vernix caseosa for babies with obvious soothing effect and a preparation method thereof, so as to solve the problem that the existing skin care products have poor soothing effect.
[0008] In order to solve the above technical problems, the present invention provides a plant bionic vernix caseosa for babies with obvious soothing effect, comprising the following components in parts by weight: main component: 1-40 parts of shea butter; 0.1-20 parts of cetearyl alcohol; 0.1-30 parts of caprylic / capric triglyceride; 0.1-35 parts of beeswax; 0-10 parts of active ingredients; and 0-60 parts of auxiliary materials.
[0009] Furthermore, the active component is phytosterols.
[0010] Furthermore, the auxiliary agent includes 0-15 parts of behenic acid glyceryl ester; 0-10 parts of jojoba esters; 0-10 parts of C10-18 fatty acid triglycerides; SymRelief 1000-2.0 parts; 0-10 parts of linseed oil; and 0-5 parts of sunflower seed oil.
[0011] Furthermore, the glyceryl behenate is Compritol 888CG glyceryl behenate.
[0012] Furthermore, the C10-18 fatty acid triglycerides are LIPOCIRE A PELLETS.
[0013] On the other hand, the present invention also provides a method for preparing the plant bionic vernix caseosa for babies with obvious soothing effect as described above, comprising the following steps: step S1, weighing phase A according to the formula and adding it to an oil pan, heating it to 80-85°C, stirring at a speed of 30-50rpm, and obtaining a premix after the material is completely dissolved; step S2, filtering the premix while hot and pumping it into a main pot, turning on the main pot for stirring at a speed of 30-50rpm, adding phase B while stirring, and continuing to stir until it is fine and uniform to obtain a colloid; step S3, stirring and cooling to 40-45°C, and after the colloid is uniform and fine, continuing to stir for 20-30min at a stirring speed of 20-25rpm to obtain the plant bionic vernix caseosa for babies with obvious soothing effect.
[0014] Furthermore, the phase A includes ceramide NP, shea butter, cetearyl alcohol, caprylic / capric triglyceride, beeswax, behenic acid glyceryl, jojoba esters, phytosterols and C10-18 fatty acid triglycerides; the phase B includes flaxseed oil and sunflower seed oil.
[0015] Furthermore, the phase A includes ceramide NP, shea butter, cetearyl alcohol, caprylic / capric triglyceride, beeswax, jojoba esters, phytosterols and C10-18 fatty acid triglycerides; and the phase B includes flaxseed oil and sunflower seed oil.
[0016] Furthermore, the phase A includes shea butter, cetearyl alcohol, caprylic / capric triglyceride, beeswax, behenic acid glyceryl, jojoba esters, phytosterols and C10-18 fatty acid triglycerides; the phase B includes SymRelief 100, flaxseed oil and sunflower seed oil.
[0017] The beneficial effect of the present invention is that the plant bionic vernix caseosa for babies with obvious soothing effect and the preparation method thereof are achieved by combining natural shea butter, medical white vaseline, natural beeswax and liquid oil caprylic / capric triglyceride in an emulsion system to play a skeleton role, cooperate with the active components to effectively penetrate the skin, play the effect of isolation, soothing and anti-inflammatory, enhance the skin's moisturizing and protective capabilities, and can effectively inhibit and soothe the baby's skin problems such as children's eczema.
[0018] Other features and advantages of the present invention will be described in the following description, and partly become apparent from the description, or understood by practicing the present invention. The purpose and other advantages of the present invention are realized and obtained by the structures particularly pointed out in the description and the drawings.
[0019] In order to make the above-mentioned objects, features and advantages of the present invention more obvious and easy to understand, preferred embodiments are given below and described in detail with reference to the accompanying drawings. BRIEF DESCRIPTION OF THE DRAWINGS
[0020] In order to more clearly illustrate the specific implementation methods of the present invention or the technical solutions in the prior art, the drawings required for use in the specific implementation methods or the description of the prior art will be briefly introduced below. Obviously, the drawings described below are some implementation methods of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.
[0021] Figure 1 A bar graph showing the IL-1α content detection results involved in some embodiments;
[0022] Figure 2 A bar graph showing the PEG2-containing fortification detection results involved in some embodiments is shown. DETAILED DESCRIPTION
[0023] In order to make the purpose, technical solution and advantages of the embodiments of the present invention clearer, the technical solution of the present invention will be clearly and completely described below in conjunction with the accompanying drawings. Obviously, the described embodiments are part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.
[0024] In this embodiment, specifically, the Compritol 888CG behenic acid glyceryl ester is selected from Gattefossé | Compritol 888CG; the LIPOCIRE A PELLETS is selected from Gattefossé LIPOCIRE A PELLETS; and the SymRelief 100 is selected from SymRelief Xinminshu 100.
[0025] Embodiment 1:
[0026] Phase A:
[0027] Ceramide NP 1 part;
[0028] 30 parts of shea butter;
[0029] 5 parts of cetearyl alcohol;
[0030] Caprylic / capric triglyceride 18.8 parts;
[0031] Beeswax 15 parts;
[0032] Compritol 888CG Glyceryl Behenate 5 parts;
[0033] 5 parts of jojoba esters;
[0034] 5 parts of phytosterols;
[0035] LIPOCIRE A PELLETS (C10-18 fatty acid triglycerides) 5 parts;
[0036] Phase B:
[0037] SymRelief 100 0.2 parts;
[0038] 5 parts linseed oil;
[0039] 5 parts sunflower seed oil.
[0040] The preparation method of Example 1 comprises the following steps:
[0041] Step S1, weigh phase A according to the formula, add it into an oil pan, heat it to 80-85°C, stir it at a speed of 30 rpm, and obtain a premix after the material is completely dissolved;
[0042] Step S2, filter the premix while hot and pump it into the main pot, start stirring the main pot at a speed of 30 rpm, add phase B while stirring, and continue stirring until it is fine and uniform to obtain a colloid;
[0043] Step S3, stirring and cooling to 40-45°C, and after the colloid is uniform and fine, continuing stirring for 20 minutes at a stirring speed of 20 rpm to obtain plant bionic vernix caseosa for infants with obvious soothing effect.
[0044] Embodiment 2:
[0045] Phase A:
[0046] Ceramide NP 0.5 parts;
[0047] 20 parts of shea butter;
[0048] 5 parts of cetearyl alcohol;
[0049] Caprylic / capric triglyceride 28.5 parts;
[0050] Beeswax 20 parts;
[0051] Compritol 888CG Glyceryl Behenate 5 parts;
[0052] 3 parts of jojoba esters;
[0053] 3 parts of phytosterols;
[0054] LIPOCIRE A PELLETS (C10-18 fatty acid triglycerides) 5 parts;
[0055] Phase B:
[0056] 5 parts linseed oil;
[0057] 5 parts sunflower seed oil.
[0058] The preparation method of embodiment 2 comprises the following steps:
[0059] Step S1, weigh phase A according to the formula, add it into an oil pan, heat it to 80-85°C, stir it at a speed of 30 rpm, and obtain a premix after the material is completely dissolved;
[0060] Step S2, filter the premix while hot and pump it into the main pot, start stirring the main pot at a speed of 30 rpm, add phase B while stirring, and continue stirring until it is fine and uniform to obtain a colloid;
[0061] Step S3, stirring and cooling to 40-45°C, and after the colloid is uniform and fine, continuing stirring for 20 minutes at a stirring speed of 20 rpm to obtain plant bionic vernix caseosa for infants with obvious soothing effect.
[0062] Embodiment 3:
[0063] Phase A:
[0064] 25 parts of shea butter;
[0065] 10 parts of cetearyl alcohol;
[0066] Caprylic / capric triglyceride 17.9 parts;
[0067] Beeswax 15 parts;
[0068] Compritol 888CG Glyceryl Behenate 1 part;
[0069] Jojoba Esters 8 parts;
[0070] 8 parts of phytosterols;
[0071] LIPOCIRE A PELLETS (C10-18 fatty acid triglycerides) 10 parts;
[0072] Phase B:
[0073] SymRelief 100 0.1 portion;
[0074] 5 parts linseed oil;
[0075] 5 parts sunflower seed oil.
[0076] The preparation method of Example 3 comprises the following steps:
[0077] Step S1, weigh phase A according to the formula, add it into an oil pan, heat it to 80-85°C, stir it at a speed of 30 rpm, and obtain a premix after the material is completely dissolved;
[0078] Step S2, filter the premix while hot and pump it into the main pot, start stirring the main pot at a speed of 30 rpm, add phase B while stirring, and continue stirring until it is fine and uniform to obtain a colloid;
[0079] Step S3, stirring and cooling to 40-45°C, and after the colloid is uniform and fine, continuing stirring for 20 minutes at a stirring speed of 20 rpm to obtain plant bionic vernix caseosa for infants with obvious soothing effect.
[0080] In this embodiment, specifically, beeswax, Chinese medicine beeswax has a long history of medicinal use. Modern research has found that the main components of beeswax are esters formed by hexadecanoic acid and triacontanol, and also include some alkanes, free long-chain fatty acids, and free long-chain fatty alcohols. In the past 10 years, research has found that the main pharmacologically active components of beeswax are the long-chain fatty alcohol family (D-002) and the long-chain fatty acid family (D-003). The pharmacological activities include anti-ulcer, anti-skin inflammation, hypolipidemic, anti-oxidation, etc., and it can play a good role as a skeleton raw material in the emulsion system.
[0081] In the present embodiment, specifically, shea butter, outward appearance is light yellow grease, is soft solid at room temperature. Its melting point is between 34-45 ℃, when applied to skin, easily melts on skin, good smearability, and has a thin protective film left on the skin surface, making the skin feel quite soft and moisturizing. Because shea butter contains triglyceride up to 80%, and unsaponifiable matter about 9%-13%, has good skin care effect, contains terpene alcohol in unsaponifiable matter and cinnamic acid ester of resin alcohol etc. simultaneously, and these esters have good anti-inflammatory effect and the effect of promoting wound healing, can well play skeleton raw material in emulsion system.
[0082] In this embodiment, specifically, vaseline is a mineral oil that can lock in moisture and moisturize due to its water-insoluble property. Vaseline is a basic ingredient in many cosmetics and skin care products, especially when used on dry skin, it can provide a good moisturizing effect and can serve as a good skeleton material in an emulsion system.
[0083] In this embodiment, specifically, phytosterols have important physiological active effects on the human body, have high permeability to the skin, can reduce lipoprotein, enhance lipase activity, defend against erythema, inhibit skin inflammation, maintain moisture on the skin surface, prevent skin aging, etc.
[0084] Efficacy test:
[0085] 1. Test basis: The test was carried out according to the "Detection method of pro-inflammatory factors (IL-1α) and inflammatory mediators (PGE2) content based on SLS-EpiKut model".
[0086] 2. Purpose and Principle: This test uses sodium dodecyl sulfate to stimulate the 3D epidermal skin model (EpiKutis) (Batch No.: ES220704, provided by Guangdong Boxi Biotechnology Co., Ltd.) to construct an in vitro skin injury model, and evaluate the soothing effect of the sample to be tested by detecting the changes in the content of pro-inflammatory factors (IL-lα) and inflammatory mediators (PGE2) in the skin model after the sample is applied.
[0087] Skin contact with highly irritating test substances or ultraviolet rays can cause clinical acute damage to the skin barrier, leading to dry skin and erythema. Anionic surfactant SLS has amphiphilic (hydrophilic and lipophilic) characteristics. When it comes into contact with the skin at a high concentration, it can damage the skin barrier, especially the lipid components and cell membranes in the barrier. The most typical clinical symptom of skin barrier damage is redness of the skin, indicating an inflammatory response.
[0088] Inflammatory factors and inflammatory mediators are relevant indicators that characterize inflammatory responses. After SLS stimulation, inflammatory factors are secreted in large quantities, while after the action of active ingredients, inflammatory factors are significantly reduced, thereby achieving the effect of repairing skin barrier damage.
[0089] IL-1α is a non-hydrophobic polypeptide that can only be released outside the cell after the cell membrane is damaged. The reduction in the content of inflammatory factors after the action of the test substance indicates that it has a soothing effect.
[0090] Prostaglandin PGE2 is a metabolite of arachidonic acid, which is mainly synthesized by cyclooxygenase. PGE2 can dilate blood vessels, cause erythema, and induce clinical symptoms of inflammatory pain. The PGE2 content is minimized after the test substance acts on it, indicating that it has a soothing effect.
[0091] Therefore, the soothing effect of the test substance can be evaluated by observing the changes in the content of the model's proinflammatory factor IL-lα and the inflammatory mediator PGE2 after administration.
[0092] 3. Main equipment
[0093] CO2 incubator (Thermo, 150i), clean bench (Suzhou Antai, SW-CJ-lF), and microplate reader (BioTek, Epoch).
[0094] 4. Test Methods
[0095] 4.1 Test scheme is shown in Table 1 below.
[0096] Table 1
[0097]
[0098] Specifically, blank control (BC): no induced injury treatment, no drug treatment; negative control (NC): SLS-induced injury, no drug treatment; positive control (PC): SLS-induced injury, 0.01% dexamethasone treatment; sample group: SLS-induced injury, sample working solution treatment.
[0099] 4.2 Working fluid configuration
[0100] (1) Preparation of 0.2% SLS working solution: Take 1 mL of 0.4% SLS solution and add 1 mL of PBS to prepare 0.2% SLS working solution.
[0101] (2) Positive control group (0.01% dexamethasone) working solution preparation: 2 μL of 10% stock solution was dissolved in 2 mL of culture medium to prepare 0.01% dexamethasone.
[0102] 4.3 Model drug administration
[0103] (1) According to the test scheme in Table 1, transfer the model to a 6-well plate (add 0.9 mL EpiGrowth culture medium in advance) and mark the test group number on the 6-well plate.
[0104] (2) Add 12.5 μL of SLS solution and 12.5 μL of sample working solution of corresponding concentration to the surface of the sample group, distribute the samples on the surface of the model, and place them in a CO2 incubator (37°C, 5% CO2) for incubation for 24 h.
[0105] (3) After the incubation, the test substance remaining on the surface of the model was cleaned with sterile PBS solution, and the residual liquid inside and outside the model was wiped off with a sterile cotton swab.
[0106] 4.4 Symptom Factor Test
[0107] After 24 hours of incubation, the culture medium of the 3D epidermal skin model was collected in an EP tube. After collection, the samples to be tested by ELISA were placed in a -80°C refrigerator for freezing and stored, and the test and analysis were performed according to the operating instructions of the ELISA kit.
[0108] 5. Statistical Analysis of Results
[0109] GraphPad Prism was used for graphing, and the results were expressed as Mean ± SD. t-test was used for statistical analysis between groups. P < 0.05 was considered to be significantly different, and P < 0.01 was considered to be extremely significantly different.
[0110] 6. Test results
[0111] 6.1, 1L-lα test results are shown in Table 2 below.
[0112] Table 2
[0113]
[0114]
[0115] Specifically, when the t-test method was used for statistical analysis, compared with the BC group, the significance was indicated by #, P-value < 0.05 was indicated by #, and P-value < 0.01 was indicated by ##; compared with the NC group, the significance was indicated by *, P-value < 0.05 was indicated by *, and P-value < 0.01 was indicated by **.
[0116] See also Figure 1 ,like Figure 1As shown, the columns from left to right in the figure are BC, NC, PC, plant bionic vernix 1, plant bionic vernix 2 and plant bionic vernix 3; compared with the BC group, the IL-lα secretion level of the NC group was significantly increased, indicating that the stimulation conditions of this test were effective; compared with the NC group, the IL-1α secretion level of the PC group was significantly decreased, indicating that the positive control of this test was effective; compared with the NC group, the sample can significantly reduce the IL-lα content.
[0117] 6.2, PEG2 test results are shown in Table 3 below.
[0118] Table 3
[0119]
[0120]
[0121] Specifically, when the t-test method was used for statistical analysis, compared with the BC group, the significance was indicated by #, P-value < 0.05 was indicated by #, and P-value < 0.01 was indicated by ##; compared with the NC group, the significance was indicated by *, P-value < 0.05 was indicated by *, and P-value < 0.01 was indicated by **.
[0122] See also Figure 2 ,like Figure 2 As shown in the figure, the columns from left to right are BC, NC, PC, plant bionic vernix 1, plant bionic vernix 2 and plant bionic vernix 3; compared with the BC group, the PEG2 secretion level of the NC group was significantly increased, indicating that the stimulation conditions of this test were effective. Compared with the NC group, the PEG2 secretion level of the PC group was significantly reduced, indicating that the positive control of this test was effective. Compared with the NC group, the sample can significantly reduce the PEG2 content.
[0123] In summary, the plant bionic vernix caseosa for babies with obvious soothing effect of the present invention and its preparation method are achieved by combining natural shea butter, medical white vaseline, natural beeswax and liquid oil caprylic / capric triglyceride in an emulsion system to play a skeleton role, assisted by a liquid crystal emulsifier, and cooperating with active ingredients to effectively penetrate the skin, thereby achieving the effects of isolation, soothing and anti-inflammatory, enhancing the skin's moisturizing and protective capabilities, and can effectively inhibit and soothe the baby's skin problems such as children's eczema.
[0124] In the several embodiments provided in this application, it should be understood that the disclosed systems, devices and methods can be implemented in other ways. The device embodiments described above are only schematic. For example, the division of the units is only a logical function division. There may be other division methods in actual implementation. For example, multiple units or components can be combined or integrated into another system, or some features can be ignored or not executed.
[0125] Based on the above ideal embodiments of the present invention, the relevant staff can make various changes and modifications without departing from the technical concept of the present invention through the above description. The technical scope of the present invention is not limited to the contents of the specification, and its technical scope must be determined according to the scope of the claims.
Claims
1. A plant bionic vernix caseosa for infants with obvious soothing effect, characterized in that: The composition includes the following components in parts by weight: Main components: 1-40 parts of shea butter; 0.1-20 parts of cetearyl alcohol; 0.1-30 parts of caprylic / capric triglyceride; 0.1-35 parts of beeswax; Active ingredient 0-10 parts; Auxiliary materials 0-60 parts.
2. The plant bionic vernix caseosa for infants with obvious soothing effect as claimed in claim 1, characterized in that: The active ingredients are phytosterols.
3. The plant bionic vernix caseosa for infants with obvious soothing effect as claimed in claim 1, characterized in that: The auxiliary agent includes 0-15 parts of behenic acid glyceryl ester; 0-10 parts of jojoba esters; 0-10 parts of C10-18 fatty acid triglycerides; 0-2.0 parts of SymRelief 100; 0-10 parts of linseed oil; and 0-5 parts of sunflower seed oil.
4. The plant bionic vernix caseosa for infants with obvious soothing effect as claimed in claim 3, characterized in that: The glyceryl behenate is Compritol 888 CG glyceryl behenate.
5. The plant bionic vernix caseosa for infants with obvious soothing effect as claimed in claim 3, characterized in that: The C10-18 fatty acid triglycerides are LIPOCIRE A PELLETS.
6. A method for preparing the plant bionic vernix caseosa for infants with obvious soothing effect as claimed in any one of claims 1 to 5, characterized in that: The steps include: Step S1, weigh phase A according to the formula, add it into an oil pan, heat it to 80-85°C, stir it at a speed of 30-50rpm, and obtain a premix after the material is completely dissolved; Step S2, filter the premix while hot and pump it into the main pot, start stirring the main pot at a speed of 30-50 rpm, add phase B while stirring, and continue stirring until it is fine and uniform to obtain a colloid; Step S3, stirring and cooling to 40-45°C, and after the colloid is uniform and fine, continuing stirring for 20-30 minutes at a stirring speed of 20-25 rpm to obtain plant bionic vernix caseosa for infants with obvious soothing effect.
7. The preparation method according to claim 6, characterized in that: The phase A includes ceramide NP, shea butter, cetearyl alcohol, caprylic / capric triglyceride, beeswax, behenic acid glyceryl, jojoba esters, phytosterols and C10-18 fatty acid triglycerides; The phase B includes linseed oil and sunflower seed oil.
8. The preparation method according to claim 6, characterized in that: The phase A includes ceramide NP, shea butter, cetearyl alcohol, caprylic / capric triglyceride, beeswax, jojoba esters, phytosterols and C10-18 fatty acid triglycerides; The phase B includes linseed oil and sunflower seed oil.
9. The preparation method according to claim 6, characterized in that: The phase A comprises shea butter, cetearyl alcohol, caprylic / capric triglyceride, beeswax, behenic acid glyceryl, jojoba esters, phytosterols and C10-18 fatty acid triglycerides; The Phase B includes SymRelief 100, linseed oil, and sunflower seed oil.
